Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a
commercial stage medical robotics company, today announced that it
is updating its previous release that was made on March 7, 2018 to
incorporate certain disclosures that are required under the NYSE
AMERICAN Company Guide Sections 401(h) and 610(b). Included below
are these additional disclosures along with the previously
disclosed financial results for the fourth quarter and year end
December 31, 2017. This announcement does not represent any
change or amendment to the Company’s financial statements, reported
results or to its Annual Report on Form 10-K for the fiscal year
ended December 31, 2017.
Recent Highlights and Accomplishments:
- Total revenue for the fourth quarter
2017 increased 22% year-over-year to $547,000, from $448,000 in the
fourth quarter of 2016. For the full year 2017, total revenue
increased 41% to $1,559,000. Gross margin for the full year 2017
and 2016 was 68% and 74%, respectively.
- Raised $10.4 million, net of financing
costs, in our follow-on public offering.
- Subsequent to December 31, 2017 and as
March 6, 2018, the Company raised $3.5 million for the issuance
1,193,556 shares of common stock upon the exercise of 1,193,556
warrants at an exercise price of $2.95 per share.
- During the fourth quarter, we repaid
our Notes Payable with the Massachusetts Life Sciences Center and
also issued 193,509 shares of common stock to repay the Notes
Payable with a former shareholder.
- We obtained a Medical Device License in
Canada, which enables us to sell the MyoPro in Canada.
- Expanded sales and marketing team and
increased marketing activity to promote MyoPro accessibility to
more individuals in the U.S. and internationally. This includes
joint patient screening events with clinical and rehabilitation
partners.
- Continued the roll out of MyoPro
Centers of Excellence at O&P practice organizations. We
currently have 36 U.S. locations offering the MyoPro line of
powered orthosis.
- Announced publication of peer-reviewed
clinical research conducted by the Ohio State University School of
Medicine. The study concluded that upper extremity impairment is
significantly reduced and subjects improved their ability to
perform activities of daily living with use of the MyoPro. These
results exceeded the clinically important difference threshold of
standard impairment tests.
- Increased recognition by the clinical
community. This includes recent presentations made at the American
Society of Hand Therapists (”ASHT”), American Academy Physical
Medicine & Rehab (“AAPM&R”) Assembly and the American
Congress of Rehabilitation and Medicine (“ACRM”).
Paul R. Gudonis, Chairman & CEO of Myomo, stated: “2017
was an important year for Myomo as we continued to build our
operational and commercial capabilities for the MyoPro product
line. During the year, we completed our IPO and follow-on offering
to raise growth capital to fund our transition from our controlled
launch phase to now scaling up operations. In 2018, we look forward
to continued execution of our business plan, and our mission to
restore functionality to the many individuals with upper limb
paralysis. We continue our efforts to bring awareness to veterans
and the broader clinical and patient communities, as we target this
large unmet need.”
Financial Highlights for the Fourth Quarter and Year End
December 31, 2017
Three monthsended
Period-to-period
Twelve months
ended
Period-to-
period
December 31, change December 31, change
2017 2016 $ % 2017 2016
$ % Revenue $ 547,412 $ 448,093 $ 99,319 22 % $
1,558,866 $ 1,103,277 $ 455,589 41 % Cost of revenue 203,972
95,830 108,142 113 % 505,280 282,164
223,116 79 % Gross margin $ 343,440 $ 352,263 $
(8,823 ) (3 )% $ 1,053,586 $ 821,113 $ 232,473 28 % Gross
margin% 63 % 79 % (16 )% 68 % 74
% (6 )%
Quarter Ended December 31, 2017 Financial
Results
Total revenue was $547,000 for the three months ended
December 31, 2017; an increase of $99,000, or 22%, as compared
to the three months ended December 31, 2016.
Gross margin was 63% for the quarter ended December 31,
2017, as compared to 79% for the three months ended
December 31, 2016. The change in gross margin was primarily
due to revenue recognized in the fourth quarter of 2016 relating to
payments received for minimum purchase requirements under our
distribution agreement for which there were no units required to be
shipped.
Research and development expenses were $357,000, a decrease of
$50,000, or 12%, during the three months ended December 31,
2017, as compared to the three months ended December 31,
2016.
Selling, general and administrative costs of $1,803,000
increased $760,000, or 73%, during the three months ended
December 31, 2017, as compared to the three months ended
December 31, 2016. The increased costs were primarily due to
increased employee compensation costs and professional fees as we
transitioned to a publicly traded company in 2017.
Interest and other expense, net was $84,000 during the three
months ended December 31, 2017, as compared with a net expense
of $114,000 in the three months ended December 31, 2016.
The Company’s net loss for the quarter ended December 31,
2017 amounted to $1,900,000, compared with a net loss of $1,211,000
for the corresponding 2016 period. Net loss available to common
stockholders for the quarter ended December 31, 2017 was
$1,900,000 or ($0.25) per share, compared with a net loss available
to common stockholders of $1,404,000, or ($1.25) per share, for the
corresponding year ago period.
Adjusted EBITDA 1 for the quarter ended December 31, 2017
was a loss of $1,770,000, compared with a loss of $1,073,000 for
the corresponding 2016 period. A reconciliation of GAAP to this
non-GAAP financial measure has been provided in the financial
statement tables included in this press release. An explanation of
this measure is also included below under the heading “Non-GAAP
Financial Measures.”
Twelve Months Ended December 31, 2017 Financial
Results
Total revenue increased by $456,000, or 41%, during the year
ended December 31, 2017, as compared to the year ended
December 31, 2016. During the year ended December 31,
2017, product revenue increased $358,000, or 33%, versus the
comparable period of 2016. We recognized $118,000 of grant revenue
during the year ended December 31, 2017 as compared to $21,000
for the year ended December 31, 2016.
Gross margin decreased to 68% for the year ended
December 31, 2017, as compared to 74% in the comparable 2016
period, reflecting $104,000 more in revenue recognized in 2016
relating to payments received for minimum purchase requirements
under our distribution agreement for which there were no units
required to be shipped, inventory reserves recorded as a result of
introduction of our MyoPro 2 products and lower margins on
demonstration units sold in 2017. These reductions were partially
offset by an increase in grant revenue in the 2017 period
associated with research projects, without incurring any additional
incremental costs.
Research and development expenses were $1,752,000, an increase
of $631,000 or 56%, primarily due to increased compensation related
expense, which included an incentive bonus to an engineering
executive and additional engineering personnel costs.
Selling, general, and administrative expenses were $5,850,000,
an increase of $2,875,000 or 97%, primarily due to increases in
personnel and other headcount related costs for additional
administrative and sales staff hired, increased professional and
other public company costs, as we prepared for our initial public
offering and transitioned to a publicly traded company and
additional expenses for marketing and clinical research to support
our sales and reimbursement efforts.
Interest and other expense was $5,549,000 in the twelve months
ended December 31, 2017 as compared with a net expense of
$342,000 in the twelve months ended December 31, 2016. This
change was due primarily to the debt discount on convertible
notes.
The Company’s net loss for the twelve months ended
December 31, 2017 amounted to $12,097,000, compared with a net
loss of $3,617,000 for the corresponding 2016 period. Net loss
available to common stockholders for the twelve months ended
December 31, 2017 was $12,659,000 or ($2.93) per share,
compared with a net loss available to common stockholders of
$4,384,000 or ($4.13) per share, for the corresponding year ago
period.
Adjusted EBITDA for the twelve months ended December 31,
2017 was a loss of $6,257,000, compared with a loss of $3,173,177
for the corresponding 2016 period. A reconciliation of GAAP to this
non-GAAP financial measure has been provided in the financial
statement tables included in this press release.
Cash and Cash Equivalents
Cash on hand at December 31, 2017 was $12,959,000, compared
to $797,000 at December 31, 2016. The increase in cash
reflects the $14.8 million in net proceeds from our public
offerings in 2017, $2.9 million from our concurrent private
placement and $1.8M of additional convertible notes issued during
the year. This was partially offset by cash used in operating
activities and by $1.2 million in principal and interest
payments made to repay our Note Payable with the Massachusetts Life
Sciences Center.
Conference Call and Webcast Information
Myomo hosted a conference call on, March 7, 2018 at 4:30
p.m. EST. A replay of the conference call will be available
approximately one hour after completion of the live conference call
at the Investor Relations page. A
dial-in replay of the call will be available until March 21,
2018; please dial 1-877-344-7529 from the U.S. or 1-412-317-0088
internationally and provide the passcode of 10117217.
Receipt of Audit Opinion with Going Concern
Qualification
As previously disclosed in its Annual Report on Form 10-K for
the fiscal year ended December 31, 2017, which was filed with the
Securities and Exchange Commission on March 12, 2018, the Company’s
audited financial statements contained a going concern explanatory
paragraph in the audit opinion from its independent registered
public accounting firm. This announcement does not represent any
change or amendment to the Company’s financial statements or to its
Annual Report on Form 10-K for the fiscal year ended December 31,
2017.
About Myomo
Myomo, Inc. is a commercial stage medical robotics company that
offers expanded mobility for those suffering from neurological
disorders and upper limb paralysis. Myomo develops and markets the
MyoPro product line. MyoPro is a powered upper limb orthosis
designed to support the arm and restore function to the weakened or
paralyzed arms of patients suffering from CVA stroke, brachial
plexus injury, traumatic brain or spinal cord injury, ALS or other
neuromuscular disease or injury. It is currently the only marketed
device that, sensing a patient’s own EMG signals through
non-invasive sensors on the arm, can restore an individual’s
ability to perform activities of daily living, including feeding
themselves, carrying objects and doing household tasks. Many are
able to return to work, live independently and reduce their cost of
care. Myomo is headquartered in Cambridge, Massachusetts, with
sales and clinical professionals across the U.S. For more
information, please visit www.myomo.com.
Forward Looking Statements
This press release contains forward-looking statements regarding
the Company’s future business expectations, including the scale-up
of commercial operations, the expansion of our MyoPro line to
Canada, and the therapeutic potential of our products, which are
subject to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
only predictions and may differ materially from actual results due
to a variety of factors.
These factors include, among other things:
- our sales and commercialization
efforts;
- our ability to achieve reimbursement
from third-party payers for our products;
- our dependence upon external sources
for the financing of our operations;
- our ability to effectively execute our
business plan; and
- our expectations as to our clinical
research program and clinical results.
More information about these and other factors that potentially
could affect our financial results is included in Myomo’s filings
with the Securities and Exchange Commission, including those
contained in the risk factors section of the Company’s quarterly
reports on Form 10-Q filed with the Commission. The Company
cautions readers not to place undue reliance on any such
forward-looking statements, which speak only as of the date made.
Although the forward-looking statements in this release of
financial information are based on our beliefs, assumptions and
expectations, taking into account all information currently
available to us, we cannot guarantee future transactions, results,
performance, achievements or outcomes. No assurance can be made to
any investor by anyone that the expectations reflected in our
forward-looking statements will be attained, or that deviations
from them will not be material and adverse. The Company disclaims
any obligation subsequently to revise any forward-looking
statements to reflect events or circumstances after the date of
such statements or to reflect the occurrence of anticipated or
unanticipated events.
Non-GAAP Financial Measures
Myomo has provided in this release of financial information that
has not been prepared in accordance with generally accepted
accounting principles in the United States, or GAAP. This
information includes Adjusted EBITDA. This non-GAAP financial
measure is not in accordance with, or an alternative for, GAAP and
may be different from similar non-GAAP financial measures used by
other companies. Myomo believes that the use of this non-GAAP
financial measures provides supplementary information for investors
to use in evaluating operating performance and in comparing its
financial measures with other companies in Myomo’s industry, many
of which present similar non-GAAP financial measures. Adjusted
EBITDA is EBITDA adjusted for the impact of the write off of
unamortized debt discount associated with conversion of convertible
notes into common stock and warrants, stock based-compensation the
impact of the fair value revaluation of our derivative liabilities
and the loss on early extinguishment of debt. Non-GAAP financial
measures that Myomo uses may differ from measures that other
companies may use. This non-GAAP financial measure disclosed by
Myomo is not meant to be considered superior to or a substitute for
results of operations prepared in accordance with GAAP, and should
be viewed in conjunction with, GAAP financial measures. Investors
are encouraged to review the reconciliation of this non-GAAP
measure to its most directly comparable GAAP financial measure. A
reconciliation of GAAP to the non-GAAP financial measures has been
provided in the tables included as part of this press release.
MYOMO, INC.
CONDENSED STATEMENTS OF
OPERATIONS
Three months endedDecember 31, Twelve
months endedDecember 31, 2017 2016
2017 2016 Revenue $ 547,412 $ 448,093 $
1,558,866 $ 1,103,277
Cost of revenue 203,972
95,830 505,280 282,164
Gross margin
343,440 352,263 1,053,586 821,113
Operating expenses: Research and development 356,867
406,618 1,751,731 1,120,951 Selling, general and administrative
1,802,584 1,042,642 5,849,969 2,975,164
Total operating expenses 2,159,451
1,449,260 7,601,700 4,096,115
Loss from
operations (1,816,011 ) (1,096,997 ) (6,548,114 ) (3,275,002 )
Other expense (income) Loss on early extinguishment of debt
135,244 — 135,244 — Change in fair value of derivative liabilities
(52,429 ) — (116,795 ) — Debt discount on convertible notes — —
5,172,000 — Interest and other expense, net 1,450
114,300 358,916 342,020 84,265
114,300 5,549,365 342,020
Net loss
(1,900,276 ) (1,211,297 ) (12,097,479 ) (3,617,022 ) Deemed
discount – accreted preferred stock discount — (27,185 ) (274,011 )
(108,739 ) Cumulative dividend to Series B-1 preferred stockholders
— (165,473 ) (287,779 ) (658,293 )
Net loss available to common stockholders $
(1,900,276 ) $ (1,403,955 ) $ (12,659,269 ) $ (4,384,054 )
Weighted average number of common shares outstanding: Basic
and diluted 7,559,309 1,124,080 4,317,864
1,060,892
Net loss per share available to common
stockholders: Basic and diluted $ (0.25 ) $ (1.25 ) $ (2.93 ) $
(4.13 )
MYOMO, INC.
CONDENSED BALANCE SHEETS
December 31, 2017 2016
(revised) ASSETS Current Assets: Cash and cash
equivalents $ 12,959,373 $ 797,174 Accounts receivable 297,039
114,506 Inventories 201,155 82,435 Prepaid expenses and other
388,275 152,337 Total Current Assets
13,845,842 1,146,452 Restricted cash 52,000 52,000 Deferred
offering costs — 438,237 Equipment, net 77,150 21,563
Total Assets $ 13,974,992 $ 1,658,252
LIABILITIES,
REDEEMABLE AND CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY
(DEFICIENCY) Current Liabilities: Notes payable, shareholder $
— $ 876,458 Notes payable, MLSC, current — 1,193,984 Accounts
payable and other accrued expenses 1,277,236 714,010 Accrued
interest — 149,580 Derivative liabilities 39,930 — Deferred revenue
168,006 67,263 Total Current Liabilities
1,485,172 3,001,295 Convertible promissory notes, net of debt
discount — 2,204,235 Convertible promissory notes, related party —
1,180,000 Accrued interest — 130,937 Deferred revenue, net of
current portion 44,042 — Total Liabilities
1,529,214 6,516,467 Redeemable and Convertible
Preferred Stock: Series B-1 convertible preferred stock — 8,174,693
Series A-1 convertible preferred stock — 4,497,548
Total Redeemable and Convertible Preferred Stock —
12,672,241 Commitments and Contingencies — —
Stockholders’ Equity (Deficiency) Common stock 1,114 112
Undesignated preferred stock — — Additional paid-in capital
47,423,915 5,351,204 Accumulated deficit (34,972,787 ) (22,875,308
) Treasury stock (6,464 ) (6,464 ) Total
Stockholders’ Equity (Deficiency) 12,445,778
(17,530,456 ) Total Redeemable and Convertible Preferred
Stock and Stockholders’ Equity (Deficiency) 12,445,778
(4,858,215 ) Total Liabilities, Redeemable and
Convertible Preferred Stock and Stockholders’ Equity(Deficiency) $
13,974,992 $ 1,658,252
MYOMO, INC.
CONDENSED STATEMENTS OF CASH
FLOWS
For the years ended December 31, 2017
2016 CASH FLOWS FROM OPERATING ACTIVITIES Net loss $
(12,097,479 ) $ (3,617,022 ) Adjustments to reconcile net loss to
net cash used in operations: Depreciation 11,415 7,731 Stock-based
compensation 279,508 94,094 Amortization of debt discount 17,765
5,347 Debt discount on convertible notes 5,172,000 — Inventory
reserve 42,355 — Common stock issued for services and software
license 31,845 — Change in fair value of derivative liabilities
(116,795 ) — Changes in operating assets and liabilities: Accounts
receivable (182,533 ) 1,136 Inventories (161,075 ) 120,588 Prepaid
expenses and other (235,938 ) (38,461 ) Restricted cash — (52,000 )
Deferred offering costs — (431,961 ) Accounts payable and other
accrued expenses 563,225 364,165 Accrued interest 377,503 299,175
Deferred revenue 144,785 44,538 Net cash used
in operating activities (6,153,419 ) (3,202,670 )
CASH FLOWS FROM INVESTING ACTIVITIES Purchases
of equipment (67,002 ) (1,865 ) Net cash used
in investing activities (67,002 ) (1,865 )
CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from
IPO, net of offering costs 4,368,315 — Proceeds from private
placement, net of offering costs 2,922,885 — Proceeds from FPO, net
of offering costs 10,407,706 — Proceeds from convertible promissory
notes, net 1,770,000 2,956,218 Repayment of note payable, MLSC
(1,215,900 ) — Proceeds from exercise of stock options 26,954 2,873
Proceeds from exercise of warrants 102,660 —
Net cash provided by financing activities 18,382,620
2,959,091 Net increase (decrease) in cash and cash
equivalents 12,162,199 (245,444 ) Cash and cash equivalents,
beginning of period 797,174 1,042,618 Cash and
cash equivalents, end of period $ 12,959,373 $ 797,174
MYOMO, INC.
RECONCILIATION OF GAAP NET LOSS TO
ADJUSTED EBITDA
(unaudited)
Three months endedDecember 31, Twelve
months endedDecember 31, 2017 2016
2017 2016 GAAP net loss $ (1,900,276 ) $ (1,211,298 )
$ (12,097,479 ) $ (3,617,022 ) Adjustments to reconcile to Adjusted
EBITDA: Loss on early extinguishment of debt 135,244 — 135,244 —
Interest expense 27,037 117,356 357,122 342,140 Other (income)
expense (25,587 ) (3,056 ) 1,793 (120 ) Depreciation expense 4,430
1,868 11,415 7,731 Stock-based compensation 41,286 21,906 279,508
94,094 Debt discount on convertible notes — — 5,172,000 — Change in
fair value of derivative liabilities (52,429 ) —
(116,795 ) — Adjusted EBITDA $ (1,770,295 ) $
(1,073,224 ) $ (6,257,192 ) $ (3,173,177 )
1 Adjusted EBITDA is earnings before interest, taxes,
depreciation and amortization adjusted the impact of the write-off
of unamortized debt discount associated with conversion of
convertible notes into common stock and warrants, stock
based-compensation, the impact of the fair value revaluation of our
derivative liabilities and the loss on early extinguishment of
debt.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180316005769/en/
For Myomo:ir@myomo.comorInvestor Relations:PCG
AdvisoryVivian Cervantes,
646-863-6274vivian@pcgadvisory.comorPublic
Relations:GreenoughRachel Robbins,
617-275-6521rrobbins@greenough.biz
Myomo (AMEX:MYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myomo (AMEX:MYO)
Historical Stock Chart
From Apr 2023 to Apr 2024